News

Aileron Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., to Vice President of Clinical Development, Endocrine and Metabolic Disease.

view full story

FORMA Therapeutics announced the appointment of Rob Sarisky, Ph.D. to Chief Business Officer. Dr. Sarisky most recently served as Vice President of Oncology Business Development and Licensing at Janssen Pharmaceuticals.

view full story

InnoCentive, Inc. announced a collaboration with AARP Foundation, AARP's charitable affiliate, to help advance the Foundation's cause of improving the lives of millions of older Americans who struggle to meet their basic needs for nutritious food, safe and affordable housing, adequate income, and personal connections.

view full story

Cerulean Pharma Inc. announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

view full story

Receptos Inc. announced the co-publication, with The Scripps Research Institute, of high resolution G-protein coupled receptor (GPCR) crystal structures in Science. This will enable rational drug discovery and design of GPCRs.

view full story

Cylene Pharmaceuticals established that RNA Polymerase I (Pol I) activity is essential for cancer cell survival. The findings published in Cancer Cell, show that Cylene’s Pol I inhibitor, CX-5461, selectively destroys cancer cells.

view full story

Cerulean Pharma Inc. announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC) patients.

view full story

Cerulean Pharma Inc. announced the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients.

view full story

FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

view full story

Viamet Pharmaceuticals, Inc. announced that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to develop broad-spectrum antifungal agents.

view full story